Business Wire

XPRIZE Announces New $10 Million Competition to Preserve Rainforests Across the Globe

19.11.2019 15:00:00 EET | Business Wire | Press release

Share

Today, XPRIZE, the global leader in designing and operating incentive competitions to solve humanity’s grand challenges, officially launched the $10M Rainforest XPRIZE. Registration is now open for teams interested in participating in the four-year global competition that calls on innovators to create technology capable of identifying and cataloging rainforest biodiversity and develop insights that may lead to a new bioeconomy through standing forests.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005397/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Rainforests remain undervalued, which has led to their rapid depletion over the past two decades. Having once covered 14% of the earth’s land surface, rainforests now cover a mere 6% of the planet, according to National Geographic. Specifically, the recent acceleration of the Amazon’s deforestation, due in part to illegal logging and mining as well as inefficient agricultural expansion, has added to climate insecurity around the globe. All these factors have elevated the urgency of bringing the importance of preserving these precious ecosystems to the forefront of international discourse. Knowledge of the full biodiversity must be unlocked so that private companies, corporations, governments, individuals, local communities, and indigenous people who have demonstrated a commitment to preserving the rainforests will be empowered to sustain rainforests rather than destroy them.

The Rainforest XPRIZE will reward teams that can develop effective new technology to capture the true biological diversity of rainforests and further layer additional data to show the value of protecting the natural resources within them. The current methods used to identify and catalogue biodiversity, including in situ human-led studies, remote sensing by satellites or radar, or sophisticated spectroscopy, cannot operate to scale and gather the data necessary to understand the full ecosystem wealth of rainforests in sustainable ways. The competition accelerates a new bioeconomy, while also engaging indigenous and local communities, as well as local academic institutions in developing the solution. The Rainforest XPRIZE is a call-to-action to help save rainforests through the development and implementation of transformative, scalable, and affordable technology.

Anousheh Ansari, CEO of XPRIZE, said, “Amid our 25th anniversary as an organization, it is fitting that we add to our legacy by introducing a prize that will challenge the best and brightest to develop transformative technology to incentivize the preservation of rainforests worldwide, not only for our generation, but those to follow.”

“Despite their importance in supporting life on Earth, rainforests are undervalued because we simply do not yet know everything that exists in this ancient ecosystem,” said Executive Director of the Rainforest XPRIZE Jyotika Virmani, Ph.D. “I’m excited to see the innovative technologies that will emerge from this competition and give us a better assessment of the incredible biodiversity. Our goal is for the Rainforest XPRIZE to provide new understanding and reveal the true potential of the standing forest, allowing local communities to lead the way for all of us to live in harmony with these magnificent rainforests.”

The teams of the Rainforest XPRIZE will develop sophisticated technologies to inventory rainforest biodiversity faster, affordably, and in unprecedented detail in challenging harsh environments, delivering insights to support the sustainable use and well-being of the standing forest. Interdisciplinary teams can use emerging technologies such as robotics, remote sensing, data analysis, artificial intelligence, and machine learning to survey biodiversity, deal with the challenges of a harsh environment, and demonstrate that these ecosystems are worth preserving.

Specifically, the winning team will survey biodiversity in at least three stories of a rainforest (emergent, canopy, understory, and forest floor) in eight hours to produce the most comprehensive biodiversity assessment and utilize this and other data to produce the greatest number of insights in 48 hours. Insights may include, but are not limited to, new ecological dependencies, biodiversity and climate connectivity, anthropological findings, or even sustainable societal interactions with the forest.

The competition includes seven months for team registration and three months for initial technical document submission. A total prize purse of $10M will be awarded throughout the lifespan of the prize, including up to $500K in bonus prizes for innovative approaches to species identification. Milestone prizes will also be awarded equally for up to 10 final teams that advance through the semi-finals.

Throughout the life cycle of the competition and following the grand prize awards ceremony, XPRIZE will work to support and scale the impact of the teams’ work and promote education around rainforest preservation.

The Rainforest XPRIZE originated from Future of Forests Impact Roadmap. The Future of Forests Impact Roadmap identified six areas for breakthroughs that could usher in a preferred future for the world’s forests, one in which forests live in harmony in an environment that balances a healthy ecosystem with humanity’s changing needs, including economic growth, social progress, and political stability.

The deadline for teams to register through the XPRIZE website is June 30, 2020. Beginning July 1, 2020 to September 23, 2020 teams can request late registration, that will be at the discretion of XPRIZE. For more information, and to register your intent to compete, visit rainforest.xprize.org.

XPRIZE

XPRIZE designs and operates multi-million-dollar, global competitions to incentivize the development of technological breakthroughs that accelerate humanity toward a better future. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million ANA Avatar XPRIZE and the $5 Million IBM Watson AI XPRIZE. For more information, visit xprize.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Katherine Schelbert
katherine.schelbert@xprize.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release

Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye